Purpose:To analyze the dosimetric characteristics of HDR-ICBT combined with concomitant complimentary IMRT in local advanced cervical cancer and reveal their survival outcomes Methods:Cervical cancer patients (FIGO staging: Ⅱb-Ⅳa) were retrospectively analyzed in Sichuan Cancer Hospital from 2009.12 to 2013.6.The patients received radical concomitant chemoradiotherapy.They received 45-50Gy/25f/5w EBRT with IMRT, and then 4 fractions HDR-ICBT combined with concomitant complimentary IMRT was applied to boost the dosage of residual cervical lesions.CT scanning and replanning were done for each fraction.The prescribed dose of HR-CTV and IR-CTV were 6-6.5Gy and 5-5.5Gy.DDP (40mg/m2) was used weekly during radiotherapy for 5 weeks.Kaplan Meier was used to do the survival analysis.CTCAE3.0 criteria was used to evaluate the acute and late side effects of both lower gastrointestinal tract and the genitourinary system.Results:97 patients with local advanced cervical cancer were recruited in this study with a median age of 52yr (29-76yr) and median follow-up of 24mons (3-46mons).Dosimetric analysis demonstrated that this new method not only dramatically improved the dose coverage of HR-CTV (average V100=93.2 %),but also kept the reasonable low doses to the bladder (D2cc 73.6Gy) ,sigmoid (D2cc 66.2Gy) and rectum(D2cc65.8Gy).Two-year follow-up data showed that the local control rate (LC), distant-free survival rate (DFS), overall survival rate (OS) was 95.8%, 86.0% and 89.5% respectively.The acute toxicity incidences of lower gastrointestinal tract (GI) and genitourinary system (GU) were 39.2%, 39.1% (grade 1-2) and 2.1%, 5.2% (grade 3).And the late toxicity incidences of GI and GU were 9.3%,16.5% (grade 1-2) and 2.1%,4.1% (grade 3),respectively.No grade 4 toxicity occurred in the patients.Conclusions:HDR-ICBT combined with concomitant complimentary IMRT is a feasible method to boost the dosage of cervical cancer target, preliminary clinical outcomes showed a better outcome and tolerable side effects.